Evidence for the prognostic significance of shared clones is supported by the observation that responders to anti-CD4 monoclonal therapy exhibit a greater expansion of shared CD8+ clones, detected in both blood and tumour compared to non-responders [77]. The gene discussed is CD8A; the disease is neoplasm.